Antipsychotic drugs: Class Labeling Change - Treatment During Pregnancy and Potential Risk to Newborns
Links shared publicly online about this topic.
- 466total visits
Antipsychotic drugs: Class Labeling Change - Treatment During Pregnancy and Potential Risk to Newborns
fda.gov —
Risk for abnormal muscle movements (extrapyramidal signs or EPS) and withdrawal symptoms in newborns whose mothers were treated with these drugs.
View full resource at fda.gov
Tags: Antipsychotic Medication, Muscle, Drug, Children's Health, Pregnancy, FDA, Safety
Most Recently Shared on March 3, 2011 at 8:45 pm By:
FDA re-labels antipsychotic drugs to improve safety during use in pregnancy: http://bit.ly/fAtsfJ
Advertisement
